Novavax, Inc. NVAX
today announced that enrollment has begun in a Phase 2 dose-ranging clinical
trial of its respiratory syncytial virus (RSV) vaccine candidate in women of
childbearing age. The study is being conducted in collaboration with PATH, an
international nonprofit organization that transforms global health through
innovation, which is providing approximately $2 million in funding to support
the trial.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in